Abstract
High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34+ cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction with granulocyte colony-stimulating factor (G-CSF). This approach is safe with few adverse events and produces significantly greater numbers of CD34 + cells when compared to G-CSF alone. New plerixafor initiatives include use in volunteer donors for allogeneic hematopoietic cell transplant and in other disease targets.
Original language | English (US) |
---|---|
Pages (from-to) | 23-29 |
Number of pages | 7 |
Journal | Core Evidence |
Volume | 6 |
DOIs | |
State | Published - Feb 7 2011 |
Externally published | Yes |
Keywords
- Autologous hematopoietic cell transplant
- CD34
- Granulocyte colony-stimulating factor (G-CSF)
- Lymphoma
- Myeloma
- Plerixafor
ASJC Scopus subject areas
- Reviews and References, Medical
- Pharmacology